Is ME/CFS or Long COVID robbing you of the life you deserve?
Your life matters. You matter. You deserve powerful solutions, administered with precision, backed by robust scientific evidence and clinical proof.
Oxaloacetate CFS 500 mg is a medical food clinically proven to lower fatigue in patients with Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
New research findings are helping CFS patients take their lives back.
Enter your email below for a free scientific report with actionable data on:
Frontiers in Neurology, the third-most cited open-access journal in clinical neurology with an Impact Factor of 3.552, peer-reviewed and published the results of an 82-person Randomized Clinical Trial (RCT) of...
Frontiers in Neurology, the third-most cited open-access journal in clinical neurology with an Impact Factor of 3.552, peer-reviewed and published the results of an 82-person Randomized Clinical Trial (RCT) of...
Peer-reviewed and published by the Journal of Translational Medicine, a Springer/Nature publication, a clinical trial reports significantly reduced mental and physical fatigue in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long...
Peer-reviewed and published by the Journal of Translational Medicine, a Springer/Nature publication, a clinical trial reports significantly reduced mental and physical fatigue in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long...
Oxaloacetate CFS is clinically proven to lower fatigue in the latest study peer-reviewed and published by Springer Nature’s Journal of Translational Medicine.
In the first 6 weeks of daily Oxaloacetate CFS…
In Bateman Horne Center’s 2024 randomized, controlled clinical trial published by Frontiers in Neurology, 3 months of daily Oxaloacetate CFS yielded:
Metabolomic studies in ME/CFS patients vs. normal controls indicate that oxaloacetate levels are significantly reduced in the plasma of ME/CFS patients.
The Journal of Molecular Biosystems published a 2017 clinical trial showing a statistically significant shortage of oxaloacetate in ME/CFS patients compared to a normal control group
Ordinary foodstuffs do not contain enough oxaloacetate to overcome this shortage, so the dietary management of ME/CFS patients cannot be achieved by the modification of the normal diet alone.
Are always to be used only under the supervision of a licensed healthcare provider. Provide support for the nutritional management of a specific disease or condition that has distinct and established nutritional requirements. Support those who have trouble digesting and absorbing food and certain nutrients and cannot nutritionally manage their condition through diet modification alone.
Provide supplementary nutritional support for healthy people. Are intended to affect the normal structure or function of the human body. While benaGene is a dietary supplement, Oxaloacetate CFS is not.
Oxaloacetate CFS is a medical food, a classification distinct from dietary supplements.
